Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
28 févr. 2019 08h00 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering
06 févr. 2019 00h15 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
05 févr. 2019 17h15 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
11 déc. 2018 16h05 HE
|
Aeglea BioTherapeutics, Inc.
Single, Global Pivotal Trial to Support Registration; Primary Endpoint of Arginine Reduction Expected to Initiate in Q2 2019; Topline Data Anticipated in Q1 2021 Company to Host Conference Call...
Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference
06 déc. 2018 16h05 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference
20 nov. 2018 08h00 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
08 nov. 2018 08h00 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual Meeting
26 oct. 2018 08h00 HE
|
Aeglea BioTherapeutics, Inc.
AEB5100 is an Engineered Human Enzyme with Novel Cystine Degrading Activity Presentation Today at 5:54 p.m. PT at the 2018 American Society of Nephrology (ASN) Annual Meeting AUSTIN, Texas, Oct. ...
Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress
22 oct. 2018 08h00 HE
|
Aeglea BioTherapeutics, Inc.
Pegzilarginase Monotherapy Demonstrates Anti-Tumor Activity AUSTIN, Texas, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company...
Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference
19 oct. 2018 08h00 HE
|
Aeglea BioTherapeutics, Inc.
AEB4104 is a Novel Engineered Human Enzyme with Unique Specificity for Degrading Both Homocysteine and Homocystine AEB4104 Prevents Death, Stops Disease Progression, and Reverses Liver Pathology in a...